Related Experiment Videos
Insights
Multicentre studies for cardiovascular pharmacotherapy lack external validity due to patient heterogeneity. Reliable preclinical data under uniform conditions are crucial for generalizable insights and improved patient management.
Area of Science:
- Cardiovascular pharmacotherapy research
- Clinical trial methodology
- Preclinical research
Context:
- Current cardiovascular pharmacotherapy relies on multicentre prospective studies.
- These studies suffer from patient heterogeneity (ethnic, criteria, medication variations).
- High patient exclusion rates (80-99%) compromise internal validity and generalizability.
Purpose:
- To highlight the limitations of current multicentre studies in cardiovascular pharmacotherapy.
- To emphasize the need for reliable preclinical data under controlled conditions.
- To underscore the indispensable role of clinical physiology in medical practice.
Summary:
- Multicentre studies in cardiovascular pharmacotherapy exhibit significant heterogeneity, leading to poor external validity.
- Exclusion of a large patient proportion (80-99%) impacts the generalizability of findings.
- Preclinical studies under uniform conditions are essential for robust data and predictive value.
- Clinical physiology provides foundational hemodynamic and pharmacodynamic correlations vital for medicine.
Impact:
- Findings suggest a critical need to re-evaluate the reliance on current multicentre study designs.
- Highlights the importance of preclinical research for developing effective cardiovascular treatments.
- Reinforces the foundational role of experimental and clinical physiology in advancing medical knowledge and practice.
Abstract:
Recent concepts of cardiovascular pharmacotherapy are now mainly based on results of multicentre prospective studies performed in several countries worldwide. The main disadvantage of such studies is the heterogeneity of patient-groups compared, caused by ethnic differences, variability of criteria and diverse concomitant medication. To assert internal validity of data compared, substantial section of patients (80-99%) is often excluded before evaluation. Thus, there is always a lack of external validity--the data cannot be generalised and have only a limited predictive value for management of other groups or individual patients. Consequently, we still need reliable preclinical data from animal and human studies under well defined and uniform conditions. The importance of experimental and clinical physiology is demonstrated by well-established hemodynamic rules and pharmacodynamic correlations. Clinical physiology remains an indispensable foundation of clinical medicine which cannot be replaced by formal statistics.